The Patent Finder

Toolgen Incorporated

27 patents currently held · Updated Nov 21, 2026
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 2 name spellings.

0
Ending by 2030
Feb 2032
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Dec 6, 2026
    The maintenance fee for Platform for Expressing Protein of Interest in Liver (US 11,667,934) comes due Dec 6, 2026. Unpaid by Jun 7, 2027, it lapses early.
  • 2 fees due Jun 19 to 30, 2027 · next Jun 19
  • 1 fee due Sep 5, 2027
    The maintenance fee for Method for Identifying DNA Base Editing by Means of Cytosine Deaminase (US 11,920,151) comes due Sep 5, 2027. Unpaid by Mar 6, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 1 of the patents on this record was granted since Aug 23, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 9,809,839Method for concentrating cells that are genetically altered by nucleases
In force
 · USPTO record
In forceUSPTO record
US 10,851,380Methods for Cleaving a Target DNA Using a Guide RNA Specific for the Target DNA and Cas Protein-Encoding Nucleic Acid or Cas Protein
In force
 · Medium confidence
In forceMedium confidence
US 12,473,559Cas9/RNA Complexes for Inducing Modifications of Target Endogenous Nucleic Acid Sequences in Nucleuses of Eukaryotic Cells
In force
 · High confidence
In forceHigh confidence
US 12,606,832Compositions for Inducing Modifications of Target Endogenous Nucleic Acid Sequences in Nucleuses of Eukaryotic Cells
In force
 · High confidence
In forceHigh confidence
US 12,612,632Compositions for Inducing Modifications of Target Endogenous Nucleic Acid Sequences in Nucleuses of Eukaryotic Cells
In force
 · High confidence
In forceHigh confidence
US 12,612,633Compositions for Inducing Modifications of Target Endogenous Nucleic Acid Sequences in Nucleuses of Eukaryotic Cells
In force
 · High confidence
In forceHigh confidence
US 12,612,634Compositions for Inducing Modifications of Target Endogenous Nucleic Acid Sequences in Nucleuses of Eukaryotic Cells
In force
 · High confidence
In forceHigh confidence
US 10,519,454Genome Editing Using Campylobacter Jejuni CRISPR/Cas System-Derived Rgen
In force
 · High confidence
In forceHigh confidence
US 12,509,697Oleic Acid -Enriched Plant Body Having Genetically Modified FAD2 and Production Method Thereof
In force
 · High confidence
In forceHigh confidence
US 12,286,635Oleic Acid-Enriched Plant Body Having Genetically Modified FAD2 and Production Method Thereof
In force
 · High confidence
In forceHigh confidence
10 of 27 patents shown.
Pro members see all 27.
Pro members: see all 27 patents
Also on record, not counted in the 27: 1 lapsed for an unpaid fee. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

17 pending · 20 abandoned · 4 no status recorded

Showing 1 to 10 of 41, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page.

ApplicationTitleFiledStatus
19/015,836Compositions for Inducing Modifications of Target Endogenous Nucleic Acid Sequences in Nucleuses of Eukaryotic CellsJan 10, 2025Pending
19/013,018Compositions for Inducing Modifications of Target Endogenous Nucleic Acid Sequences in Nucleuses of Eukaryotic CellsJan 8, 2025Pending
18/944,148Cells for Intravascular Transplantation Having Hemocompatibility, Method of Producing Same, and Use ThereofNov 12, 2024Pending
18/822,009Hypoimmunogenic Stem Cells, Hypoimmunogenic Cells Differentiated or Derived from Stem Cells and Method of Preparing SameAug 30, 2024Pending
18/657,145Manipulated Immunoregulatory Element and Immunity Altered TherebyMay 7, 2024Pending
18/590,251Vector for Delivering Active Agent to Nervous System, and Use ThereofFeb 28, 2024Pending
18/424,920Hemocompatible Mesenchymal Stem Cells, Preparation Method Therefor and Use ThereofJan 29, 2024Pending
18/407,597Mesenchymal Stem Cell Having Oxidative Stress Resistance, Preparation Method Therefor, and Use ThereofJan 9, 2024Abandoned
18/467,967Compositions Comprising Cas9/guide RNA Complexes for Inducing Targeted Disruption of Endogenous Genes in Eukaryotic CellsSep 15, 2023Abandoned
18/314,050Composition for Cleaving a Target DNA Comprising a Guide RNA Specific for the Target DNA and Cas Protein-Encoding Nucleic Acid or Cas Protein, and Use ThereofMay 8, 2023Abandoned
10 of 41 applications shown.
Pro members see all 41 published applications.
Pro members: see all 41 applications
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited